Dominik Berthold

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

Nicholas D. James, Johann S. de Bono, Melissa Spears et al. · New England Journal of Medicine · 2017 · 1.7K citations · Full text

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

Dominik Berthold, Gregory R. Pond, Freidele Soban et al. · Journal of Clinical Oncology · 2008 · 1.1K citations

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Karim Fizazi, Stéphanie Foulon, Joan Carles et al. · The Lancet · 2022 · 716 citations · Full text

Factorial Design, Urology, × 2 +9

Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study

Dominik Berthold, Gregory R. Pond, Martin Roessner et al. · Clinical Cancer Research · 2008 · 206 citations

Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer

Matthew D. Galsky, Sumanta K. Pal, Simon Chowdhury et al. · Cancer · 2015 · 194 citations · Full text